Israel Fernandez-Pineda1, M M Hudson2, A S Pappo2, M W Bishop2, J L Klosky3, T M Brinkman4, D K Srivastava5, M D Neel6, B N Rao6, A M Davidoff6, K R Krull4, D A Mulrooney2, L L Robison4, K K Ness4. 1. Department of Surgery, St. Jude Children's Research Hospital, 226 Danny Thomas Place, MS133, Memphis, TN, 38105, USA. israel.fernandez-pineda@stjude.org. 2. Department of Oncology, St. Jude Children's Research Hospital, 226 Danny Thomas Place, MS133, Memphis, TN, 38105, USA. 3. Department of Psychology, St. Jude Children's Research Hospital, 226 Danny Thomas Place, MS133, Memphis, TN, 38105, USA. 4. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 226 Danny Thomas Place, MS133, Memphis, TN, 38105, USA. 5. Department of Biostatistics, St. Jude Children's Research Hospital, 226 Danny Thomas Place, MS133, Memphis, TN, 38105, USA. 6. Department of Surgery, St. Jude Children's Research Hospital, 226 Danny Thomas Place, MS133, Memphis, TN, 38105, USA.
Abstract
PURPOSE: This study compared measured physical performance, health-related quality of life (HRQOL), and social role attainment between extremity sarcoma survivors and controls, and evaluated associations between disease and treatment exposures, health conditions, and performance measures. METHODS: Survivors of extremity sarcoma from the St. Jude Lifetime cohort and controls frequency matched by age-, sex-, and race completed physical performance testing and questionnaires. Survivors with Z-scores on outcome measures ≤ -2.0 SD (compared to controls) were categorized with severe impairment/limitation. RESULTS: Among 206 survivors (52.4 % male median age 36 years (range 19-65)), 37 % had low relative lean mass, 9.7 % had an ejection fraction <50 %, 51.5 % had diffusion capacity for carbon monoxide <75 %, 27.7 % had sensory and 25.2 % motor neuropathy, and 78.2 % had musculoskeletal complications. Severe impairments/limitations were present among ≥25 % of survivors on fitness, balance, and physical HRQOL measures, and among ≥15 % on strength and activity of daily living measures. Lower extremity tumor location (OR 8.23, 95 % CI 2.54-26.67, P value 0.0004) and amputation (OR 8.07, 95 % CI 3.06-21.27, P value <0.0001) were associated with poor fitness. Poor fitness was associated with increased odds of scoring <40 on the SF-36 physical component summary (OR 4.83, 95 % CI 1.95-11.99, P value 0.001) and role-physical subscale (OR 3.34, 95 % CI 1.33-8.43, P value 0.01). Survivors and controls had similar rates of marriage, independent living, employment, and college attendance. CONCLUSIONS: Extremity sarcoma survivors experience high rates of physical impairment and report lower than expected physical HRQOL. However, they are as likely as peers to be married, live independently, be employed, and attend college. IMPLICATIONS FOR CANCER SURVIVORS: Follow-up for extremity sarcoma survivors should include assessment of need for further orthopedic care and rehabilitation to address cardiopulmonary and musculoskeletal health.
PURPOSE: This study compared measured physical performance, health-related quality of life (HRQOL), and social role attainment between extremity sarcoma survivors and controls, and evaluated associations between disease and treatment exposures, health conditions, and performance measures. METHODS: Survivors of extremity sarcoma from the St. Jude Lifetime cohort and controls frequency matched by age-, sex-, and race completed physical performance testing and questionnaires. Survivors with Z-scores on outcome measures ≤ -2.0 SD (compared to controls) were categorized with severe impairment/limitation. RESULTS: Among 206 survivors (52.4 % male median age 36 years (range 19-65)), 37 % had low relative lean mass, 9.7 % had an ejection fraction <50 %, 51.5 % had diffusion capacity for carbon monoxide <75 %, 27.7 % had sensory and 25.2 % motor neuropathy, and 78.2 % had musculoskeletal complications. Severe impairments/limitations were present among ≥25 % of survivors on fitness, balance, and physical HRQOL measures, and among ≥15 % on strength and activity of daily living measures. Lower extremity tumor location (OR 8.23, 95 % CI 2.54-26.67, P value 0.0004) and amputation (OR 8.07, 95 % CI 3.06-21.27, P value <0.0001) were associated with poor fitness. Poor fitness was associated with increased odds of scoring <40 on the SF-36 physical component summary (OR 4.83, 95 % CI 1.95-11.99, P value 0.001) and role-physical subscale (OR 3.34, 95 % CI 1.33-8.43, P value 0.01). Survivors and controls had similar rates of marriage, independent living, employment, and college attendance. CONCLUSIONS:Extremity sarcoma survivors experience high rates of physical impairment and report lower than expected physical HRQOL. However, they are as likely as peers to be married, live independently, be employed, and attend college. IMPLICATIONS FOR CANCER SURVIVORS: Follow-up for extremity sarcoma survivors should include assessment of need for further orthopedic care and rehabilitation to address cardiopulmonary and musculoskeletal health.
Entities:
Keywords:
Function; Musculoskeletal sarcoma; Physical performance; Quality of life; Social role attainment; Survivor
Authors: Joshua M Drouin; Tamara C Valovich-mcLeod; Sandra J Shultz; Bruce M Gansneder; David H Perrin Journal: Eur J Appl Physiol Date: 2003-09-24 Impact factor: 3.078
Authors: Bradley J Stish; Safia K Ahmed; Peter S Rose; Carola A Arndt; Nadia N Laack Journal: Pediatr Blood Cancer Date: 2015-08-14 Impact factor: 3.167
Authors: Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Webb A Smith; Kirsten K Ness; Vijaya Joshi; Melissa M Hudson; Leslie L Robison; Daniel M Green Journal: Pediatr Blood Cancer Date: 2013-11-06 Impact factor: 3.167
Authors: Kirsten K Ness; Kevin R Krull; Kendra E Jones; Daniel A Mulrooney; Gregory T Armstrong; Daniel M Green; Wassim Chemaitilly; Webb A Smith; Carmen L Wilson; Charles A Sklar; Kyla Shelton; Deo Kumar Srivastava; Sabeen Ali; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-18 Impact factor: 44.544
Authors: Ann C Mertens; Yutaka Yasui; Yan Liu; Marilyn Stovall; Ray Hutchinson; Jill Ginsberg; Charles Sklar; Leslie L Robison Journal: Cancer Date: 2002-12-01 Impact factor: 6.921
Authors: Vesile Yildiz Kabak; Patrick Calders; Tulin Duger; Jibril Mohammed; Eric van Breda Journal: Support Care Cancer Date: 2018-09-25 Impact factor: 3.603
Authors: Michael W Bishop; Kirsten K Ness; Chenghong Li; Wei Liu; Deo Kumar Srivastava; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Alberto S Pappo; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-04 Impact factor: 4.254
Authors: Rodrigo B Interiano; Sue C Kaste; Chenghong Li; Deo Kumar Srivastava; Bhaskar N Rao; William C Warner; Daniel M Green; Matthew J Krasin; Leslie L Robison; Andrew M Davidoff; Melissa M Hudson; Israel Fernandez-Pineda; Kirsten K Ness Journal: J Cancer Surviv Date: 2017-07-01 Impact factor: 4.442
Authors: Christopher L Tinkle; Israel Fernandez-Pineda; April Sykes; Zhaohua Lu; Chia-Ho Hua; Michael D Neel; Armita Bahrami; Barry L Shulkin; Sue C Kaste; Alberto Pappo; Sheri L Spunt; Matthew J Krasin Journal: Cancer Date: 2017-07-31 Impact factor: 6.860
Authors: Angela Meyer Corr; Wei Liu; Michael Bishop; Alberto Pappo; Deo Kumar Srivastava; Michael Neel; Bhaskar Rao; Terry Wilson; Kirsten K Ness Journal: Rehabil Oncol Date: 2017-01
Authors: Samah Hayek; Todd M Gibson; Wendy M Leisenring; Jennifer L Guida; Maria Monica Gramatges; Philip J Lupo; Rebecca M Howell; Kevin C Oeffinger; Smita Bhatia; Kim Edelstein; Melissa M Hudson; Leslie L Robison; Paul C Nathan; Yutaka Yasui; Kevin R Krull; Gregory T Armstrong; Kirsten K Ness Journal: J Clin Oncol Date: 2019-12-04 Impact factor: 44.544
Authors: Samah Hayek; Tara M Brinkman; Juan C Plana; Vijaya M Joshi; Russell V Leupker; Jean B Durand; Daniel M Green; Robyn E Partin; Aimee K Santucci; Rebecca M Howell; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kirsten K Ness Journal: JAMA Oncol Date: 2020-08-01 Impact factor: 31.777
Authors: Deborah B Crom; Kirsten K Ness; Larry R Martinez; Michelle R Hebl; Leslie L Robison; Melissa M Hudson; Tara M Brinkman Journal: J Cancer Surviv Date: 2018-03-17 Impact factor: 4.442
Authors: Stephanie B Dixon; Kari L Bjornard; Nicole M Alberts; Gregory T Armstrong; Tara M Brinkman; Wassim Chemaitilly; Matthew J Ehrhardt; Israel Fernandez-Pineda; Lisa M Force; Todd M Gibson; Daniel M Green; Carrie R Howell; Sue C Kaste; Anne C Kirchhoff; James L Klosky; Kevin R Krull; John T Lucas; Daniel A Mulrooney; Kirsten K Ness; Carmen L Wilson; Yutaka Yasui; Leslie L Robison; Melissa M Hudson Journal: CA Cancer J Clin Date: 2018-01-29 Impact factor: 508.702